
Christine J. Saoud
Examiner (ID: 4595)
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1616, 1801, 1812, 1647, 1646, 1645, 2899 |
| Total Applications | 1543 |
| Issued Applications | 747 |
| Pending Applications | 209 |
| Abandoned Applications | 630 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13339813
[patent_doc_number] => 20180221446
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-09
[patent_title] => Angiogenically Effective Unit Dose Of FGF And Method Of Administering
[patent_app_type] => utility
[patent_app_number] => 15/699556
[patent_app_country] => US
[patent_app_date] => 2017-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14132
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15699556
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/699556 | Angiogenically Effective Unit Dose Of FGF And Method Of Administering | Sep 7, 2017 | Abandoned |
Array
(
[id] => 20254853
[patent_doc_number] => 12427186
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => Method for treating growth hormone deficiency employing hGH fusion protein
[patent_app_type] => utility
[patent_app_number] => 16/329317
[patent_app_country] => US
[patent_app_date] => 2017-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 3504
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16329317
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/329317 | Method for treating growth hormone deficiency employing hGH fusion protein | Aug 29, 2017 | Issued |
Array
(
[id] => 20254853
[patent_doc_number] => 12427186
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => Method for treating growth hormone deficiency employing hGH fusion protein
[patent_app_type] => utility
[patent_app_number] => 16/329317
[patent_app_country] => US
[patent_app_date] => 2017-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 3504
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16329317
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/329317 | Method for treating growth hormone deficiency employing hGH fusion protein | Aug 29, 2017 | Issued |
Array
(
[id] => 14960739
[patent_doc_number] => 20190307847
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-10
[patent_title] => METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/327760
[patent_app_country] => US
[patent_app_date] => 2017-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68598
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16327760
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/327760 | METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS | Aug 27, 2017 | Abandoned |
Array
(
[id] => 12206943
[patent_doc_number] => 20180052169
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-02-22
[patent_title] => 'TSP1 AS A MARKER FOR CANCER'
[patent_app_type] => utility
[patent_app_number] => 15/681774
[patent_app_country] => US
[patent_app_date] => 2017-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 30148
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15681774
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/681774 | TSP1 AS A MARKER FOR CANCER | Aug 20, 2017 | Abandoned |
Array
(
[id] => 15422567
[patent_doc_number] => 10544197
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-28
[patent_title] => FGF-23 epitope peptide for improving resistance to breakage and eggshell strength
[patent_app_type] => utility
[patent_app_number] => 15/675022
[patent_app_country] => US
[patent_app_date] => 2017-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 5014
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15675022
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/675022 | FGF-23 epitope peptide for improving resistance to breakage and eggshell strength | Aug 10, 2017 | Issued |
Array
(
[id] => 12117313
[patent_doc_number] => 20180000898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-04
[patent_title] => 'Method of Treating or Ameliorating Type 1 Diabetes Using FGF21'
[patent_app_type] => utility
[patent_app_number] => 15/671923
[patent_app_country] => US
[patent_app_date] => 2017-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 27990
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15671923
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/671923 | Method of Treating or Ameliorating Type 1 Diabetes Using FGF21 | Aug 7, 2017 | Abandoned |
Array
(
[id] => 12260612
[patent_doc_number] => 20180079806
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-03-22
[patent_title] => 'CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY'
[patent_app_type] => utility
[patent_app_number] => 15/668573
[patent_app_country] => US
[patent_app_date] => 2017-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 42675
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15668573
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/668573 | CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY | Aug 2, 2017 | Abandoned |
Array
(
[id] => 12051208
[patent_doc_number] => 20170327551
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-16
[patent_title] => 'METHODS OF USING COMPOSITIONS COMPRISING FUSION VARIANTS OF FGF19 POLYPEPTIDES FOR REDUCING GLUCOSE LEVELS IN A SUBJECT'
[patent_app_type] => utility
[patent_app_number] => 15/666402
[patent_app_country] => US
[patent_app_date] => 2017-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 32583
[patent_no_of_claims] => 74
[patent_no_of_ind_claims] => 14
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15666402
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/666402 | Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject | Jul 31, 2017 | Issued |
Array
(
[id] => 12624552
[patent_doc_number] => 20180100014
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-04-12
[patent_title] => BINDING PROTEINS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/659177
[patent_app_country] => US
[patent_app_date] => 2017-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 72936
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15659177
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/659177 | Beta-klotho binding proteins | Jul 24, 2017 | Issued |
Array
(
[id] => 16169516
[patent_doc_number] => 10711066
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-14
[patent_title] => Anti-canine platelet derived growth factor receptor alpha antibody
[patent_app_type] => utility
[patent_app_number] => 16/318944
[patent_app_country] => US
[patent_app_date] => 2017-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5240
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16318944
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/318944 | Anti-canine platelet derived growth factor receptor alpha antibody | Jul 19, 2017 | Issued |
Array
(
[id] => 15256503
[patent_doc_number] => 20190376985
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-12
[patent_title] => ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE
[patent_app_type] => utility
[patent_app_number] => 16/315805
[patent_app_country] => US
[patent_app_date] => 2017-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23480
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16315805
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/315805 | ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE | Jul 6, 2017 | Pending |
Array
(
[id] => 11977586
[patent_doc_number] => 20170281741
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-05
[patent_title] => 'PEPTIDE AND METHOD FOR REDUCING THE PHOSPHATE REQUIREMENT AND EXCRETIION FROM FARM ANIMALS'
[patent_app_type] => utility
[patent_app_number] => 15/623450
[patent_app_country] => US
[patent_app_date] => 2017-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 11425
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15623450
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/623450 | FGF-23 epitope peptides and methods of use thereof | Jun 14, 2017 | Issued |
Array
(
[id] => 12980830
[patent_doc_number] => 20170342488
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-30
[patent_title] => METHODS OF USING FGF19 MODULATORS
[patent_app_type] => utility
[patent_app_number] => 15/608603
[patent_app_country] => US
[patent_app_date] => 2017-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35506
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608603
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/608603 | METHODS OF USING FGF19 MODULATORS | May 29, 2017 | Abandoned |
Array
(
[id] => 17569932
[patent_doc_number] => 11318186
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-03
[patent_title] => Use of FGF21 in methods of increasing exocrine pancreatic secretion
[patent_app_type] => utility
[patent_app_number] => 16/304080
[patent_app_country] => US
[patent_app_date] => 2017-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 8132
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16304080
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/304080 | Use of FGF21 in methods of increasing exocrine pancreatic secretion | May 23, 2017 | Issued |
Array
(
[id] => 14213969
[patent_doc_number] => 20190119369
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-25
[patent_title] => METHOD OF TREATING OR PREVENTING LIVER CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 16/095021
[patent_app_country] => US
[patent_app_date] => 2017-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24778
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095021
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/095021 | METHOD OF TREATING OR PREVENTING LIVER CONDITIONS | Apr 20, 2017 | Abandoned |
Array
(
[id] => 14309665
[patent_doc_number] => 20190144536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE
[patent_app_type] => utility
[patent_app_number] => 16/092653
[patent_app_country] => US
[patent_app_date] => 2017-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44216
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16092653
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/092653 | ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE | Apr 12, 2017 | Abandoned |
Array
(
[id] => 17274456
[patent_doc_number] => 20210380654
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/604088
[patent_app_country] => US
[patent_app_date] => 2017-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11283
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604088
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/604088 | HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF | Apr 9, 2017 | Pending |
Array
(
[id] => 17274456
[patent_doc_number] => 20210380654
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/604088
[patent_app_country] => US
[patent_app_date] => 2017-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11283
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604088
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/604088 | HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF | Apr 9, 2017 | Pending |
Array
(
[id] => 11949494
[patent_doc_number] => 20170253646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-07
[patent_title] => 'Functional Peptide Analogs of PEDF'
[patent_app_type] => utility
[patent_app_number] => 15/477934
[patent_app_country] => US
[patent_app_date] => 2017-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 34283
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15477934
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/477934 | Functional Peptide Analogs of PEDF | Apr 2, 2017 | Abandoned |